EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group.

In the treatment of renal cell carcinoma both complete (CRs) and partial remissions (PRs) have been obtained using recombinant (r) interferon alpha (IFN-alpha), with response rates ranging from 0 to 31% (mean 16%). rIFN-gamma is a potent immunostimulating agent, but the clinical experience of its us...

Descripción completa

Detalles Bibliográficos
Autores principales: De Mulder, P. H., Oosterhof, G., Bouffioux, C., van Oosterom, A. T., Vermeylen, K., Sylvester, R.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1995
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033601/
https://www.ncbi.nlm.nih.gov/pubmed/7841054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033601/
https://www.ncbi.nlm.nih.gov/pubmed/7841054

Ejemplares similares